Esophageal Adenocarcinoma Methods and Protocols

(sharon) #1
267

roles and current perspectives. Exp Mol Pathol
96:98–107. https://doi.org/10.1016/j.
yexmp.2013.12.004


  1. Maroof H, Salajegheh A, Smith RA, Lam AK
    (2014) Role of microRNA-34 family in cancer
    with particular reference to cancer angiogene-
    sis. Exp Mol Pathol 97:298–304. https://doi.
    org/10.1016/j.yexmp.2014.08.002

  2. Maroof H, Salajegheh A, Smith RA, Lam AK
    (2014) MicroRNA-34 family, mechanisms of
    action in cancer: a review. Curr Cancer Drug
    Targets 14:737–751

  3. Lam A (2015) Chapter 2: Cellular and
    molecular biology of esophageal cancer. In:
    Saba NF, El-Rayes, Bassel F (eds) Esophageal
    cancer: prevention, diagnosis and therapy.
    Springer, New York, pp 25–40

  4. Amin M, Lam AK (2015) Current perspectives
    of mi-RNA in esophageal adenocarcinoma:
    roles in predicting carcinogenesis, progression
    and values in clinical management. Exp Mol
    Pathol 98:411–418. https://doi.
    org/10.1016/j.yexmp.2015.03.002

  5. Bobryshev YV, Orekhov AN, Chistiakov DA
    (2015) MicroRNAs in esophageal adenocarci-
    noma: functional significance and potential for
    the development of new molecular disease
    markers. Curr Pharm Des 21:3402–3416

  6. Chen C, Zhang Y, Zhang L, Weakley SM, Yao
    Q (2011) MicroRNA-196: critical roles and
    clinical applications in development and cancer.
    J Cell Mol Med 15:14–23. https://doi.
    org/10.1111/j.1582-4934.2010.01219.x

  7. Matsuzaki J, Suzuki H, Tsugawa H, Watanabe
    M, Hossain S, Arai E, Saito Y, Sekine S, Akaike
    T, Kanai Y, Mukaisho K, Auwerx J, Hibi T
    (2013) Bile acids increase levels of microRNAs
    221 and 222, leading to degradation of CDX2
    during esophageal carcinogenesis.
    Gastroenterology 145:1300–1311. https://
    doi.org/10.1053/j.gastro.2013.08.008

  8. Hemmatzadeh M, Mohammadi H, Karimi M,
    Musavishenas MH, Baradaran B (2016)
    Differential role of microRNAs in the patho-
    genesis and treatment of Esophageal cancer.
    Biomed Pharmacother 82:509–519. https://
    doi.org/10.1016/j.biopha.2016.05.009

  9. Derouet MF, Liu G, Darling GE (2014) MiR-
    145 expression accelerates esophageal adeno-
    carcinoma progression by enhancing cell
    invasion and anoikis resistance. PLoS One
    9:e115589. https://doi.org/10.1371/jour-
    nal.pone.0115589

  10. Wang Y, Zhao Y, Herbst A, Kalinski T, Qin J,
    Wang X, Jiang Z, Benedix F, Franke S,
    Wartman T, Camaj P, Halangk W, Kolligs FT,
    Jauch KW, Nelson PJ, Bruns CJ (2016) miR-


221 mediates chemoresistance of esophageal
adenocarcinoma by direct targeting of DKK2
expression. Ann Surg 264:804–814. https://
doi.org/10.1097/sla.0000000000001928


  1. Lynam-Lennon N, Bibby BA, Mongan AM,
    Marignol L, Paxton CN, Geiersbach K,
    Bronner MP, O'Sullivan J, Reynolds J, Maher
    SG (2016) Low miR-187 expression promotes
    resistance to chemoradiation therapy in vitro
    and correlates with treatment failure in patients
    with esophageal adenocarcinoma. Mol Med
    22. https://doi.org/10.2119/
    molmed.2016.00020

  2. Sugimura K, Miyata H, Tanaka K, Hamano R,
    Takahashi T, Kurokawa Y, Yamasaki M,
    Nakajima K, Takiguchi S, Mori M, Doki Y
    (2012) Let-7 expression is a significant deter-
    minant of response to chemotherapy through
    the regulation of IL-6/STAT3 pathway in
    esophageal squamous cell carcinoma. Clin
    Cancer Res 18:5144–5153. https://doi.
    org/10.1158/1078-0432.ccr-12-0701

  3. Hong L, Han Y, Zhang H, Li M, Gong T, Sun
    L, Wu K, Zhao Q, Fan D (2010) The prognos-
    tic and chemotherapeutic value of miR-296 in
    esophageal squamous cell carcinoma. Ann Surg
    251:1056–1063. https://doi.org/10.1097/
    SLA.0b013e3181dd4ea9

  4. Hong L, Han Y, Lu Q, Zhang H, Zhao Q, Wu
    K, Fan D (2012) Drug resistance-related
    microRNAs in esophageal cancer. Expert Opin
    Biol Ther 12:1487–1494. https://doi.org/10
    .1517/14712598.2012.711309

  5. Fassan M, Baffa R, Kiss A, Zaninotto G, Rugge
    M (2013) MicroRNA dysregulation in esopha-
    geal neoplasia: the biological rationale for
    novel therapeutic options. Curr Pharm Des
    19:1236–1241

  6. Garzon R, Marcucci G, Croce CM (2010)
    Targeting microRNAs in cancer: rationale,
    strategies and challenges. Nat Rev Drug Discov
    9:775–789. https://doi.org/10.1038/
    nrd3179

  7. Matsui D, Zaidi AH, Martin SA, Omstead AN,
    Kosovec JE, Huleihel L, Saldin LT, DiCarlo C,
    Silverman JF, Hoppo T, Finley GG, Badylak
    SF, Kelly RJ, Jobe BA (2016) Primary tumor
    microRNA signature predicts recurrence and
    survival in patients with locally advanced
    esophageal adenocarcinoma. Oncotarget
    7:81281–81291

  8. Tang S, Wu WK, Li X, Wong SH, Wong N,
    Chan MT, Sung JJ, Yu J (2016) Stratification
    of digestive cancers with different pathological
    features and survival outcomes by MicroRNA
    expression. Sci Rep 6:24466. https://doi.
    org/10.1038/srep24466


MicroRNA Detection and Esophageal Adenocarcinoma
Free download pdf